Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
57 results about "Acute renal shutdown" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The topic Acute Renal Shutdown you are seeking is a synonym, or alternative name, or is closely related to the medical condition Acute Kidney Failure. Acute Kidney Failure is a condition when the kidneys can no longer filter wastes out of blood. In this condition, there is an abrupt loss of kidney function that develops over a period of few days.
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
InactiveUS20090105173A1Increased riskPrevent ototoxicitySugar derivativesGenetic material ingredientsDiseaseEprotirome
The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
Owner:QUARK FARMACUITIKALS INC
Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
ActiveUS20080287382A1Increased riskImprove the level ofOrganic active ingredientsSenses disorderRadical radiotherapyDisease cause
The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.
Owner:QUARK FARMACUITIKALS INC
Methods of treatment of acute renal failure
ActiveUS20090082291A1Increased riskImprove the level ofOrganic active ingredientsSenses disorderDiseaseOligoribonucleotides
The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from alopecia or acute renal failure or other diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The alopecia may be induced by chemotherapy or radiotherapy, and the patient may be suffering from cancer, in particular breast cancer.
Owner:QUARK FARMACUITIKALS INC
Receptor specific atrial natriuretic peptides
Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.
Owner:GENENTECH INC
Methods for detecting or predicting kidney disease
InactiveUS20140038203A1Overcome limitationsMicrobiological testing/measurementDisease diagnosisDiseaseNephrosis
Methods of detecting or predicting the onset or magnitude of kidney diseases such as acute kidney disease (AKI), previously called acute renal failure (ARF), are provided. In various aspects, methods and kits are provided to detect specific urinary proteins associated with AKI diagnosis or prognosis such as, e.g., angiotensinogen.
Owner:MUSC FOUND FOR RES DEV
Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA
InactiveUS7910566B2Increased riskPrevent ototoxicitySugar derivativesGenetic material ingredientsDiseaseEprotirome
The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from acute renal failure or other kidney diseases comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.
Owner:QUARK FARMACUITIKALS INC
Bifunctional hormone and uses thereof
InactiveUS20090011997A1Antibody mimetics/scaffoldsTetrapeptide ingredientsDiseaseHormones regulation
A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and / or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).
Owner:THERATECHONOLGIES INC
Therapy of Kidney Diseases and Multiorgan Failure with Mesenchymal Stem Cells and Mesenchymal Stem Cell Conditioned Media
InactiveUS20080241112A1Improve kidney functionAntibacterial agentsSenses disorderMulti organOrgan dysfunction
Methods and a composition for the treatment of organ dysfunction, acute renal failure, multi-organ failure, early dysfunction of kidney transplant, graft rejection, chronic renal failure, wounds, and inflammatory disorders including media conditioned by mesenchymal stem cells are provided. Methods for modulation of growth factor and cytokine expression including administering a therapeutic amount of mesenchymal stem cells, endothelial cells derived from mesenchymal stem cells, or media conditioned by mesenchymal stem cells are also provided.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPT OF VETERANS AFFAIRS +1
Blood filtering replacement liquid prescription special for anti congealing
InactiveCN101254316AFunction increaseImprove the quality of lifeOther blood circulation devicesSurgerySodium lactateSide effect
The invention relates to a formula of a blood filtration replacement fluid which is special for citrate anticoagulation, a preparation method and a usage thereof. With the components of sodium citrate, sodium chloride, potassium chloride, sodium lactate, citric acid and so on, the replacement fluid is mainly used for blood filtration and blood dialysis filtration of the patients with acute renal failure or high risk bleeding due to multiple organ failure etc., and can solve the problems of easy occurrence of hypernatremia and alkali poisoning in the prior citrate anticoagulation, thus facilitating the clinical usage. The replacement fluid has the advantages of strong applicability, exact efficacy and low toxicity and side effects; the preparation process is simple; the quality is stable, safe and effective; the feasibility is strong; the repeatability is high; and the replacement fluid is applicable to the large-scale production and the promotion of the clinical application, thus being the ideal blood filtration replacement fluid for blood filtration, blood dialysis filtration, continuous renal replacement therapy and so on. The demand of the blood dialysis increases along with the increasing number of the patients with the end-stage renal failure year by year, so the blood filtration replacement fluid can generate more tremendous economic and social benefits.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Formulations for the transdermal administration of fenoldopam
InactiveUS6960353B2Improve compliancePharmaceutical non-active ingredientsSheet deliveryCongestive heart failure chfAcute renal shutdown
Composition of matter for application to skin to administer fenoldopam by permeation through the skin, the composition comprising fenoldopam to be administered, at a therapeutically effective rate, in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of fenoldopam for the treatment of hypertension, congestive heart failure, and chronic and acute renal failure.
Owner:ALZA CORP
Therapies for acute renal failure
InactiveUS20100105621A1Reduce rateImprove survival ratePeptide/protein ingredientsAntipyreticOsteogenic proteinsApoptosis
The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of, acute renal failure, or subject to, or at risk of, inflammation, neutrophil-mediated cell damage, and apoptosis resulting from tissue damage or injury. The methods involve the administration of certain proteins of the osteogenic protein / bone morphogenetic protein (OP / BMP) family within the TGF-β superfamily of proteins.
Owner:STRYKER CORP
Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders
The present invention relates generally to a method for the treatment of renal failure or renal hypertension and, more particularly, for improving the recovery from acute renal failure or renal hypertension by treatment with activators of soluble guanylate cyclase or stimulators of guanylate cyclase.
Owner:BAYER SCHERING PHARMA AG
Method for distinguishing between kidney dysfunctions
ActiveUS7977110B2Addressing Insufficient SensitivitySufficient specificityMicrobiological testing/measurementDisease diagnosisMammalNGAL Protein
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +1
Stem Cell, Precursor Cell, or Target Cell-Based Treatment of Multi-Organ Failure and Renal Dysfunction
Owner:UNIV OF UTAH RES FOUND +1
Methods for Enhanced Propagation of Cells
ActiveUS20100136687A1Enhancing kidney cell expansionQuality improvementCell culture active agentsUrinary disorderEnd stage renal diseaseMulti organ
The present invention relates generally to methods for the isolation and propagation of cells. For example, embodiments of the present invention relate to isolation and propagation methods for the manufacture of a large number of cells for use, for example, in biotherapeutic devices, such as devices for renal replacement therapy for the treatment of acute renal failure (ARF), acute tubular necrosis (ATN), multi-organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end-stage renal disease (ESRD).
Owner:SEASTAR MEDICAL INC
Diagnostic use of individual molecular forms of a biomarker
InactiveUS20100304413A1Strong specificityDisease diagnosisImmunoglobulinsAcute Renal InjuryNGAL Protein
Methods are provided of diagnosing, monitoring or determining the severity of disease or injury by measuring individual molecular forms of neutrophil gelatinase-associated lipocalin (NGAL) in bodily fluids, including the diagnosis and monitoring of acute renal injury leading to acute renal failure in a human or mammalian subject by determining the concentration of the free monomer form of NGAL.
Owner:BIOPORTO DIAGNOSTICS AS
Method for distinguishing between kidney dysfunctions
ActiveUS20090298047A1Creatinine level is lowMicrobiological testing/measurementDisease diagnosisMammalNormal renal function
A method for distinguishing between kidney dysfunctions in a mammal, including pre-renal azotemia, an acute renal injury that may progress to acute renal failure, and chronic kidney disease, using a urinary or circulating NGAL assay result that is compared to a predetermined NGAL cutoff level, and a single serum or plasma creatinine measurement. Typically the single creatinine measurement cannot distinguish acute renal injury from chronic kidney disease or pre-renal azotemia, a single measurement of urinary NGAL, combined with the single serum or plasma creatinine measurement, has sufficient sensitivity and specificity to distinguish acute renal injury from normal function, prerenal azotemia, and chronic kidney disease and predicts poor inpatient outcomes. Patients admitted to the emergency department of the hospital with any of acute kidney injury, prerenal azotemia, chronic kidney disease, or even normal kidney function, can be evaluated based on the single measurements of urinary or circulating NGAL, and serum or plasma creatinine. Urinary NGAL level is highly predictive of clinical outcomes, including nephrology consultation, dialysis, and admission to the intensive care unit.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +1
Systems and methods for characterizing kidney diseases
InactiveUS7138229B2Microbiological testing/measurementDisease diagnosisNephrosisInterstitial Disease
Owner:RENOVAR
Traditional Chinese preparation for treating acute renal failure
InactiveCN104225319ASignificant effectNo side effectsUnknown materialsUrinary disorderPolygonum aviculareSide effect
The invention discloses a traditional Chinese preparation for treating acute renal failure. The traditional Chinese preparation is prepared by selecting bulk drugs respectively in parts by weight as follows: 20-30 g of rhubarb, 10-20 g of cassia twig, 10-20 g of poria cocos, 10-20 g of rhizoma alismatis,10-20 g of rhizoma imperatae, 10-20 g of buffalo horn, 10-20 g of Cirsium japonicum, 10-20 g of safflower, 10-20 g of figwort roots, 8-15 g of tetrapanax papyriferus, 8-12 g of peach kernel, 8-12 g of antelope horn powder, 8-12 g of white mulberry root-bark, 8-12 g of semen lepidii, 8-12 g of polygonum aviculare and 8-12 g of dianthus superbus. All the drugs are compatible to achieve tonification and purgation in combination, and together play the function of reinforcing Qi and nourishing blood, activating blood circulation to dissipate blood stasis, clearing heat and detoxifying, achieving cathartic purpose, and alleviating water retention and freeing strangury. The traditional Chinese preparation is obvious in curative effect, free of negative or side effects and high in cure rate when used for treating acute renal failure, requires a short time for recovering renal function normality, achieves low probability of recurrence after curing and is worthy of clinical popularization and application.
Owner:范常云
Biology artificial kidney tubule bioreactor and use thereof
InactiveCN101357084AImprove survival rateProlong survival timeProsthesisMultiple organ dysfunction syndromeFiber
The invention provides a biological reaction device which replaces human kidney, consisting of a biological reactor, a peristaltic pump, a cell culture liquid constant-flow device and a constant temperature box; the biological reactor consists of a plastic shell, a pouring liquid inlet, a pouring liquid outlet, a cell culture liquid inlet, a cell culture liquid outlet, a sulfone film nanometer supporting layer and a hollow fiber pipe; the hollow fiber pipe is arranged in a concentric round; the peristaltic pump is connected with the pouring liquid inlet and the pouring liquid outlet of the biological reactor; the constant-flow device is connected with the cell culture liquid inlet and outlet of the biological reactor; the biological reactor, the peristaltic pump and the constant-flow device are arranged inside the constant temperature box; the biological reaction device has reasonable design and simple and convenient preparation, can replace the kidney function of acute renal failure and multiple organ dysfunction syndrome patient in long-term or leads the similar patients to gradually recover the self-kidney tissue and other functions, thus improving the survival rate of the multiple organ dysfunction syndrome patient and prolonging the survival time of the multiple organ dysfunction syndrome patients.
Owner:ZHEJIANG UNIV
Diagnostic method for detecting acute kidney injury using heat shock protein 72 as a sensitive biomarker
InactiveUS20130065239A1Microbiological testing/measurementDisease diagnosisReal-Time PCRsWestern blot
The invention relates to a reliable, easy-to-implement non-invasive diagnostic method for detecting early acute kidney injury by measuring the concentration of a biomarker in urine samples, said biomarker being selected from heat shock proteins of the 70 KDa family. More specifically, the invention relates to the identification of heat shock protein 72, whereby said biomarker is identified by means of ELISA and Western blot or by means of the level of RNAm using real-time RT-PCR. The invention helps to solve the current problem that exists in medicine whereby it is not possible to detect acute renal failure in the early stages or the severity of the renal damage in order to treat the patient in a timely manner with an effective therapy.
Owner:UNIV NAT AUTONOMA DE MEXICO
Methods for enhanced propagation of cells
ActiveUS9029144B2Quality improvementProlong lifeArtificial cell constructsCell culture active agentsEnd stage renal diseaseMedicine
The present invention relates generally to methods for the isolation and propagation of cells. For example, embodiments of the present invention relate to isolation and propagation methods for the manufacture of a large number of cells for use, for example, in biotherapeutic devices, such as devices for renal replacement therapy for the treatment of acute renal failure (ARF), acute tubular necrosis (ATN), multi-organ failure (MOF), sepsis, cardiorenal syndrome (CRS) and end-stage renal disease (ESRD).
Owner:SEASTAR MEDICAL INC
Bicarbonate-based solutions for dialysis therapies
InactiveCN1496272ASlow changeReduce modificationPharmaceutical delivery mechanismUrinary disorderCritically illMedicine
Owner:NIKKISO COMPANY
Methods for treating hypertension and angina using salts of optically pure (-) amlodipine
Methods and compositions are disclosed utilizing the optically pure (-) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of amlodipine. The (-) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of (-) amlodipine as a calcium channel antagonist such as cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure, without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.
Owner:SEPACOR INC
Use of survivin to treat kidney failure
The present invention relates generally to methods of for the prevention and treatment for renal disease. In particular, the invention relates to methods of prevention and treatment of mammals, including humans, which are at risk of developing renal failure. This is generally in the field of treatment or prevention of acute renal failure by administration of the anti-apoptotic molecule survivin. The invention also includes the treatment of kidney transplants (renal allografts) to prolong survival of the graft during cold ischemia and immediately after transplantation.
Owner:VLAAMS INTERUNIVERSITAIR INST VOOR BIOTECHNOLOGIE VZW +1
3-(6-chloro-3-oxo-3,4-dihydro-(2H)-1,4-benzoxazin-4-yl) propanoic acid derivatives and their use as KMO inhibitors
Compounds of formula (I)wherein:R1 is heteroaryl optionally substituted by methyl, ethyl, halo or ═O; andR2 is H, methyl or ethyl.and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.
Owner:THE UNIV COURT OF THE UNIV OF EDINBURGH
Methods for production of growth-promoting proteins and peptides for kidney epithelial cells
InactiveUS7160864B2Shorten the timePromote growthSugar derivativesPeptide/protein ingredientsADAMTS ProteinsFactor ii
Novel growth peptides derived from protein factors having molecular weights of about 22 and 45 kDa stimulate mitogenic activity of epithelial, but not fibroblastic cells, in particular, kidney epithelial cells. A source of the factors is scrape-wounded kidney epithelial cells in culture. Synthetic peptides having sixteen amino acids or less, in particular a hexapeptide, YPQGNH (SEQ ID NO: 2) maintain the mitogenic activity. The peptide AQPYPQGNHEASYG (14-Ser) (SEQ ID NO: 15) is effective in reversing acute renal failure in animals. The growth-promoting characteristics of the 22 and 45 kDa proteins and the peptides are useful in treating and diagnosing patients with kidney disease. Nucleotide sequences that encode the factor are useful to develop probes to locate similar factors, to identify genetic disorders involving the factor, and to produce the factor by genetic recombinant methods. The nucleotide sequences and fragments thereof, are also useful for diagnosis and treatment of kidney disorders.
Owner:CHICAGO UNIV OF THE
Diagnostic test for renal injury
ActiveUS8313919B2Satisfactory linearityStrong specificityMicrobiological testing/measurementDisease diagnosisBacteriuriaBlood plasma
A method is provided of diagnosing and monitoring acute renal injury leading to acute renal failure in a human or mammalian subject by determining the ratio of the concentration of neutrophil gelatinase-associated lipocalin (NGAL) in urine to that in plasma or serum.
Owner:BIOPORTO DIAGNOSTICS AS
Adipose tissue-derived stem cells for veterinary use
The invention relates to adipose tissue-derived stem cells for veterinary use. The invention provides compositions and methods for making and using the adipose-derived stem cells for treating non-human mammals for various medical conditions. In particular, the invention provides methods and compositions useful for repair of bone fractures and for treatment of "dry eye" conditions, acute renal failure, and chronic renal failure in non-human mammals.
Owner:CELL4VET
Treating acute renal failure with soluble thrombomodulin variants
InactiveUS20100087368A1Preventing acute renal failureAvoid failurePeptide/protein ingredientsMammal material medical ingredientsProtein activationMortality rate
The present invention provides a method for preventing and / or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.
Owner:INDIANA UNIV RES & TECH CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com